Download full-text PDF |
Source |
---|
JMIR Public Health Surveill
January 2025
Stiftung Gesundheitswissen, Berlin, Germany.
Background: Prevalences of mental disorders are increasing worldwide. However, many people with mental health problems do not receive adequate treatment. An important factor preventing individuals from seeking professional help is negative attitudes toward psychotherapeutic treatment.
View Article and Find Full Text PDFAppl Physiol Nutr Metab
January 2025
Chronic Disease Innovation Centre, Winnipeg, Canada;
Risk factors contributing to cardiovascular diseases (CVD) can be addressed through behavior modification, including changes in diet and physical activity. In 2021, The Wellness Institute (WI), located at Seven Oaks General Hospital, created a virtual cardiometabolic risk reduction program in response to COVID-19 pandemic public health restrictions, encompassing virtual health coaching and lifestyle education. The objective was to evaluate the acceptability, adherence, efficacy and engagement of the WI online cardiometabolic and weight loss program.
View Article and Find Full Text PDFPhysiol Rev
January 2025
Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland.
Physical activity is a meaningful part of life, which starts before birth and lasts until death. There are many health benefits to be derived from physical activity, hence, regular engagement is recommended on a weekly basis. However, these recommendations are often not met.
View Article and Find Full Text PDFPLoS One
January 2025
Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
Purpose: Treatment of peripheral artery disease (PAD) in the region below the knee (BTK) is dissatisfying as failure of treated target lesions (TLF) is frequent and diagnostic imaging is often challenging. In the BTK-region metallic drug-eluting stents (mDES) yielded best results concerning primary patency (PP), but also annihilate signal in magnetic resonance angiography (MR-A). A recently introduced non-metallic drug eluting bioresorbable Tyrocore® vascular scaffold (deBVS), that offers an option for re-treatment of lesions due to its full degradation within 3-4 years after placement, was investigated with respect to its compatibility with MR-A to unimpededly depict previously treated target lesions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!